Breaking News

MilliporeSigma Invests $76M to Expand Bioconjugation Facility in Missouri

Will grow its ADC manufacturing capabilities and triple existing capacity.

Author Image

By: Charlie Sternberg

Associate Editor

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, is investing $76 million to expand its ADC manufacturing capabilities and capacity at its Bioconjugation Center of Excellence facility in St. Louis, Missouri.   This investment will triple existing capacity and enhance the company’s contract development and manufacturing organization (CDMO) offering, reinforcing its commitment to clients and patients.   With additional capacity and by scaling utiliti...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters